Novel Nanotechnology as an Accurate Screening and Prediction Tool for Prostate Cancer

Novel Nanotechnology as an Accurate Screening and Prediction Tool for Prostate Cancer
prostate cancerResearchers at the Boston University Medical Center, NorthShore University HealthSystem and Northwestern University developed a new nanotechnology capable of identifying tumor risk and especially of predicting cancer progression. The study is entitled “Nanocytological Field Carcinogenesis Detection to Mitigate Overdiagnosis of Prostate Cancer: A Proof of Concept Study” and was recently published in the journal PLOS ONE. Prostate cancer is the second most common cancer in men, with almost one million new cases diagnosed every year worldwide. It is a curable cancer that can range from slow-growing tumors (more common) to rapidly progressing aggressive tumors. An early diagnosis of the disease is crucial and it can be made through a blood analysis for prostate-specific antigens (PSA). However, this recommended screening tool is currently being debated because it is unable to predict which of the individuals with high PSA levels will actually develop an aggressive cancer. Therefore, better prognostic tools are required. Clinicians believe that prostate cancer might be often over-diagnosed and over-treated, resulting in u
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *